Abstract:The receptor tyrosine kinase AXL is an emerging driver of cancer recurrence, while its molecular mechanism remains unclear. In this study we investigated how AXL regulated the disease progression and poor prognosis in non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC). We performed AXL transcriptome analysis from TCGA datasets, and found that AXL expression was significantly elevated in NSCLC and TNBC correlating with poor prognosis, epithelial-mesenchymal transition (EMT) and immune-tolerant tumor microenvironment (TME). Knockdown of AXL or treatment with two independent AXL antibodies (named anti-AXL and AXL02) all diminished cell migration and EMT in AXL-high expressing NSCLC and TNBC cell lines. In a mouse model of 4T1 TNBC, administration of anti-AXL antibody substantially inhibited lung metastases formation and growth, accompanied by reduced downstream signaling activation, EMT and proliferation index, as well as an increased apoptosis and activated anti-tumor immunity. We found that AXL was abundantly activated in tumor nodule-infiltrated M2-macrophages. A specific anti-AXL antibody blocked bone marrow-derived macrophage (BMDM) M2-polarization in vitro. Targeting of AXL in M2-macrophage in addition to tumor cell substantially suppressed CSF-1 production and eliminated M2-macrophage in TME, leading to a coordinated enhancement in both the innate and adaptive immunity reflecting M1-like macrophages, mature dendritic cells, cytotoxic T cells and B cells. We generated a novel and humanized AXL-ADC (AXL02-MMAE) employing a site-specific conjugation platform. AXL02-MMAE exerted potent cytotoxicity against a panel of AXL-high expressing tumor cell lines (IC 50 < 0.1 nmol/L) and suppressed in vivo growth of multiple NSCLC and glioma tumors (a minimum efficacy dose<1 mg/kg). Compared to chemotherapy, AXL02-MMAE achieved a superior efficacy in regressing large sized tumors, eliminated AXL-H tumor cell-dependent M2-macrophage infiltration with a robust accumulation of inflammatory macrophages and mature dendritic cells. Our results support AXL-targeted therapy for treatment of advanced NSCLC and TNBC.

AXL in Cancer: a Modulator of Drug Resistance and Therapeutic Target

AXL Inhibition Induces DNA Damage and Replication Stress in Non–Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors

AXL Receptor Tyrosine Kinase As a Promising Anti-Cancer Approach: Functions, Molecular Mechanisms and Clinical Applications

AXL Receptor in Cancer Metastasis and Drug Resistance: When Normal Functions Go Askew

Axl Inhibitors As Novel Cancer Therapeutic Agents.

Recent Discovery and Development of AXL Inhibitors As Antitumor Agents

AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations

Progress of the role of Axl in drug resistance of leukemia and the targeted therapy

Research progress of Axl inhibitors.

Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling.

AXL antibody and AXL-ADC mediate antitumor efficacy via targeting AXL in tumor-intrinsic epithelial-mesenchymal transition and tumor-associated M2-like macrophage

Does Axl have potential as a therapeutic target in pancreatic cancer?

AXL receptor as an emerging molecular target in colorectal cancer

AXL receptor tyrosine kinase inhibition improves the anti-tumor effects of CD8+ T cells by inducing CD103+ dendritic cell-mediated T cell priming

AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells.

The Role of Axl in Drug Resistance and Epithelial-to-mesenchymal Transition of Non-Small Cell Lung Carcinoma.

AXL and MET in Hepatocellular Carcinoma: A Systematic Literature Review

Gas6/AXL pathway: immunological landscape and therapeutic potential

Targeting AXL in mesothelioma: From functional characterization to clinical implication

Gas6/Axl Axis Contributes To Chemoresistance And Metastasis In Breast Cancer Through Akt/Gsk-3 Beta/Beta-Catenin Signaling

Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling.